Filtered By:
Drug: Colcrys

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 87 results found since Jan 2013.

Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis
ConclusionsThese data suggest colchicine, in addition to guideline-directed medical therapy following acute coronary syndrome reduces MACE, cerebrovascular accidents, and rates of urgent revascularization at 2 years of follow-up.
Source: Cardiology and Therapy - January 6, 2023 Category: Cardiology Source Type: research

Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions
This article reviews current pharmacotherapeutic options for prevention of stroke in NVAF, paying special attention to their use in particular clinical settings (e.g.: cardioversion, catheter ablation). We also aim to review new drug candidates that have entered clinical studies in this indication.EXPERT OPINION: Oral anticoagulant therapy (OAT) remains the mainstay for ischemic stroke prophylaxis in NVAF in patients at risk. Several oral (asundexian, milvexian) and parenteral (abelacimab, osocimab, xisomab, IONIS-FXIRX, fesomersen) factor XIa inhibitors are under development. These new compounds appear to be associated wi...
Source: Expert Opinion on Pharmacotherapy - November 18, 2022 Category: Drugs & Pharmacology Authors: Antonio G ómez-Outes M Luisa Su árez-Gea Alejandro-Isidoro P érez-Cabeza Jose Manuel Garc ía-Pinilla Source Type: research

Evaluating the Utility of Colchicine in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Abstract: Colchicine has demonstrated promising effects in inhibiting local and systemic inflammation during acute coronary syndrome (ACS). However, the efficacy of colchicine in ACS is controversial. We performed a meta-analysis to assess the utility of colchicine in ACS by systematically searching randomized controlled trials. Recurrent myocardial infarction, coronary revascularization, and stroke were included as efficacy endpoint parameters whereas safety endpoints chosen were all-cause mortality, cardiovascular mortality, infectious events, and gastrointestinal (GI) adverse events. Nine identified studies were inc...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Review Article Source Type: research

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research

Effect of different doses of colchicine on high sensitivity C-reactive protein in patients with acute minor stroke or transient ischemic attack: A pilot randomized controlled trial
CONCLUSION: Early treatment with low dose of colchicine reduced hsCRP levels in the patients with acute minor ischemic stroke and TIA.PMID:36041708 | DOI:10.1016/j.ejps.2022.106288
Source: European Journal of Pharmaceutical Sciences - August 30, 2022 Category: Drugs & Pharmacology Authors: Baoshi Yuan Xia Meng Anxin Wang Siying Niu Xuewei Xie Jing Jing Hao Li Liguo Chang Yongjun Wang Jiejie Li Source Type: research

Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials
Introduction Inflammation is emerging as an important risk factor for atherosclerotic cardiovascular disease and has been a recent target for many novel therapeutic agents. However, comparative evidence regarding efficacy of these anti-inflammatory treatment options is currently lacking. Methods and analysis This systematic review will include randomised controlled trials evaluating the effect of anti-inflammatory agents on cardiovascular outcomes in patients with known cardiovascular disease. Studies will be retrieved from Medline, Embase, the Cochrane Central Register of Controlled Trials, as well as clinical trial regi...
Source: BMJ Open - June 27, 2022 Category: General Medicine Authors: Boczar, K. E., Shin, S., Bezzina, K. A., Geejo, A., Pearson, A. L., Shahab, S., Fehlmann, C. A., Visintini, S., Beanlands, R., Wells, G. A. Tags: Open access, Cardiovascular medicine Source Type: research

Gout Medicine Colchicine May Also Help Fight Heart Failure
MONDAY, May 23, 2022 -- The anti-inflammatory benefits of a common gout medicine may help save the lives of heart failure patients, researchers say. The medication, colchicine, could also reduce the risk of heart attack and stroke in patients whose...
Source: Drugs.com - Daily MedNews - May 23, 2022 Category: General Medicine Source Type: news

The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis
CONCLUSIONS: The use of colchicine reduces the risk of stroke in patients with a history of coronary artery disease, without a significant increase in gastrointestinal and myopathy/myalgia adverse effects.PMID:35538274 | DOI:10.1007/s11239-022-02659-9
Source: Atherosclerosis - May 10, 2022 Category: Cardiology Authors: Claire X Y Goh Ying Kiat Tan Choon Han Tan Aloysius S T Leow Jamie S Y Ho Natalie H W Tan Sherill Goh Andrew F W Ho Vijay K Sharma Bernard P L Chan Leonard L L Yeo Benjamin Y Q Tan Source Type: research